GHIT Fund Announces $4.5 Million Investment in TB Diagnostics Development
Deal News | Apr 23, 2025 | PR Newswire Cision GHIT Fund
The Global Health Innovative Technology (GHIT) Fund has committed USD 4.5 million to the development of tuberculosis diagnostics by partnering with Fluxus, Inc., Fujirebio, Inc., and Heidelberg University Hospital. This initiative is part of a broader effort to combat TB, an infectious disease claiming approximately 1.25 million lives annually. The project will focus on creating an ultrasensitive point-of-care diagnostic tool based on Fluxus' technology, promising significant improvements in accessibility and accuracy of TB diagnosis. Additionally, GHIT Fund announced an investment of USD 0.1 million for research on Chagas disease and leishmaniasis, collaborating with prominent Japanese universities and the Drugs for Neglected Diseases initiative. Since its inception, the GHIT Fund has invested USD 255 million in combating neglected diseases, aligning with global health goals to enhance healthcare accessibility in vulnerable populations worldwide.
Sectors
- Healthcare
- Pharmaceuticals and Biotechnology
Geography
- Japan – The GHIT Fund is based in Japan, and significant collaborations are taking place with Japanese entities.
- USA – Fluxus, Inc., a partner in the TB diagnostics project, is based in the United States.
- Germany – Heidelberg University Hospital in Germany is a partner in developing the new TB diagnostics.
Industry
- Healthcare – This industry classification is relevant as the article discusses the development of diagnostic technologies for tuberculosis, a healthcare-related issue.
- Pharmaceuticals and Biotechnology – The entities involved are pharmaceutical and biotechnology research companies partnering to develop diagnostics and treatments for TB and neglected diseases.
Financials
- USD 4.5 million – Investment for the development of diagnostics for tuberculosis by the GHIT Fund.
- USD 0.1 million – Investment for a drug discovery project concerning Chagas disease and leishmaniasis.
- JPY 38.2 billion (USD 255 million) – Total GHIT Fund investments since 2013.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Global Health Innovative Technology (GHIT) Fund | Investor | Charity | An international public-private partnership fund, based in Japan, aimed at addressing neglected diseases. |
| Fluxus, Inc. | Development Partner | Company | A US-based diagnostic developer involved in TB diagnostic development. |
| Fujirebio, Inc. | Development Partner | Company | A developer of clinical diagnostics based in Japan, partnering in the TB diagnostic effort. |
| Heidelberg University Hospital | Development Partner | Company | A medical institution in Germany partnering in the TB diagnostics project. |
| Kitasato University | Research Partner | Company | A Japanese university involved in the Chagas disease and leishmaniasis research. |
| Nagasaki University | Research Partner | Company | A Japanese university collaborating on the Chagas disease and leishmaniasis project. |
| University of Tokyo | Research Partner | Company | Engaged in the Chagas disease and leishmaniasis research initiative. |
| Drugs for Neglected Diseases initiative (DNDi) | Research Partner | Charity | An international nonprofit organization working towards solutions for neglected diseases. |